Literature DB >> 7381031

Single-dose kinetics of intravenous vancomycin.

D J Krogstad, R C Moellering, D J Greenblatt.   

Abstract

The pharmacokinetic properties of intravenously administered vancomycin were studied in four healthy volunteers. Reversible adverse effects (flushing, tachycardia, pruritus) occurred in two subjects who received high-dose rapid intravenous infusions. Distribution of vancomycin proceeded as a biphasic process in all four subjects. The initial distribution half-life (t1/2 alpha) was less than 8 minutes in all cases, with intermediate half-lives (t1/2 pi) varying from 0.43 to 1.48 hour and elimination half-lives (t1/2 beta) varying from 4.7 to 11.2 hours. Vancomycin clearance was less than creatinine clearance, probably because of serum protein binding, which was determined to be 55 per cent.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7381031     DOI: 10.1002/j.1552-4604.1980.tb01696.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  37 in total

1.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

3.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

4.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

6.  Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis.

Authors:  K J Wilson; J T Mader
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.

Authors:  Christian Joukhadar; Satish Pillai; Christine Wennersten; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

8.  Effects of hepatic function on vancomycin clinical pharmacology.

Authors:  N Brown; D H Ho; K L Fong; L Bogerd; A Maksymiuk; R Bolivar; V Fainstein; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients.

Authors:  P Charbonneau; I Harding; J J Garaud; J Aubertin; F Brunet; Y Domart
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

10.  Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Authors:  H Hanberger; L E Nilsson; R Maller; B Isaksson
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.